Condition: Ovarian Neoplasms · Endometrial Neoplasms · Endometrial Cancer · Sponsor: McGill University
This study aims to develop and validate a test for detecting ovarian and endometrial cancers early. It relies on detecting somatic mutations that are associated with these cancers from a uterine pap test. A saliva sample is also collected that acts as an internal control and has the ability to detect deleterious germline mutations associated with common hereditary cancers (such as breast, ovarian, endometrial, colon, and pancreatic cancers). A machine learning classifier is then used to discriminate between cancer and benign disease.
This description comes directly from the study's public registry record.
Dr. Lucy Gilbert, MD,MSc,FRCOG · (514) 934-1934 · lucy.gilbert@mcgill.ca
Dr. Claudia Martins, PhD · (514) 934-1934 · claudia.martins@mcgill.ca
Always discuss trial participation with your own doctor first.
| Royal Victoria Hospital (Glen Site) | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02288676